{
    "id": 903,
    "fullName": "KIT W557R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT W557R lies within the juxtamembrane domain (exon 11) of the Kit protein (PMID: 15790786). W557R has been identified in the scientific literature (PMID: 15869870) but has not been biochemically characterized and therefore, its effect on Kit protein funciton is unknown (PubMed, Sep 2018).",
            "references": [
                {
                    "id": 425,
                    "pubMedId": 15790786,
                    "title": "Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15790786"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 12219,
                    "pubMedId": 15869870,
                    "title": "KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15869870"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "W557R",
    "createDate": "07/08/2014",
    "updateDate": "05/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 136906,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54727437T>A",
        "cDna": "c.1669T>A",
        "protein": "p.W557R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11238,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 995,
                "profileName": "KIT W557R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11232,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988).",
            "molecularProfile": {
                "id": 27931,
                "profileName": "KIT W557R KIT L576P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 995,
            "profileName": "KIT W557R",
            "profileTreatmentApproaches": [
                {
                    "id": 1918,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT W557R"
                }
            ]
        },
        {
            "id": 27931,
            "profileName": "KIT W557R KIT L576P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136906,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54727437T>A",
            "cDna": "c.1669T>A",
            "protein": "p.W557R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136907,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54727437T>A",
            "cDna": "c.1669T>A",
            "protein": "p.W557R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}